Table 1.
Characteristics of the analysis sample (N=1,559).
| N (weighted %) | |
|---|---|
| Age (years) | |
| 30–39 | 418 (37.1%) |
| 40–49 | 454 (25.5%) |
| 50–59 | 353 (17.9%) |
| 60–69 | 220 (12.4%) |
| 70–79 | 114 (7.0%) |
| Race/Ethnicity* | |
| Black | 429 (27.5%) |
| Hispanic | 515 (33.0%) |
| White | 615 (39.5%) |
| Socioeconomic Status | |
| Low | 632 (22.8%) |
| Middle | 641 (48.3%) |
| High | 286 (28.9%) |
| Body Mass Index (kg/m2) | |
| <25.0 | 407 (26.8%) |
| 25.0–29.9 | 612 (39.5%) |
| 30.0+ | 541 (33.7%) |
| Physical Activity (PASE) | |
| Low (<100) | 434 (25.4%) |
| Middle (100–250) | 731 (47.2%) |
| High (250+) | 394 (27.5%) |
| Smoking | |
| Never | 600 (39.4%) |
| Former | 455 (29.4%) |
| Current | 503 (31.2%) |
| Alcohol Consumption (drinks/day) | |
| None | 499 (24.8%) |
| <1 | 575 (41.1%) |
| 1–2.9 | 311 (25.2%) |
| 3+ | 174 (8.9%) |
| Heart disease (% Yes) | 152 (9.4%) |
| Diabetes (% Yes) | 190 (9.7%) |
| High blood pressure (% Yes) | 481 (25.8%) |
| Depression (% Yes) | 259 (14.1%) |
| Anti-inflammatory medication** (% Yes) | 732 (53.5%) |
| Current cancer treatment (% Yes) | 16 (1.4%) |
| Taking hormone medication (% Yes) | 25 (1.4%) |
*
unweighted
**
Anti-inflammatory and other medications that may could affect CRP levels: Blood form & coagulant/anti-platelet agent (clopidogrel, ticlopidine); Cardiovascular/antilipemics/hmg-coa reductase inhibitors (statins); Non-statin anti-cholesterol drugs; Beta-blockers; Calcium channel blockers; Select ACE inhibitors (captopril, ramipril, fosinopril); Rosiglitazone, pioglitazone; Angiotensin II receptor agonists (Losartan, Valsartan, Irbesartan, Olmesartan, Candesartan, Telmisartan); Aspirin; Naproxen; Ibuprofen